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http:WHAT THIS PAPER ADDS
This is the ﬁrst systematic review with a methodological assessment of studies on measurement properties of all
available disease speciﬁc PROMs for patients with intermittent claudication. Taking into account the limited
amount and the quality of the evidence, the PAD quality of life questionnaire (PADQOL), Intermittent claudi-
cation questionnaire (ICQ) and the Vascular quality of life questionnaire (VascuQol) might be appropriate
PROMs for health related quality of life, while the Walking impairment questionnaire (WIQ) and Estimate
ambulation capacity by history questionnaire (EACH-Q) appear suitable PROMs for functional status. Method-
ologically sound studies of the measurement properties of a few selected instruments are needed to increase
quality and uniformity in reporting outcome of these patients.Objective: The aim was to critically appraise, compare, and summarize the quality of the measurement
properties of all available disease speciﬁc patient reported outcome measures (PROMs) on health related quality
of life and functional status validated in patients with intermittent claudication (IC).
Methods: A systematic search was carried out in Embase and Medline (last search November 18, 2013). The
quality of the identiﬁed studies was assessed per measurement property according to the COnsensus-based
Standards for the selection of health Measurements Instruments (COSMIN) checklist. Data on the measurement
properties were extracted to determine a level of evidence per measurement property per instrument.
Results: Forty three studies were found evaluating 10 health related quality of life and two functional status
PROMs. Evidence for the existence of subscales (structural validity) and for internal consistency (interrelatedness
of items within subscales) for PROMs was generally poor. Evidence for construct validity was limited. Accuracy
and reproducibility of PROMs were often uncertain, since reliability studies were mostly performed in small
patient samples. Responsiveness, or the ability of PROMs to detect change over time, was hardly ever studied.
Conclusion: The quality of the validation of most disease speciﬁc PROMs for IC is alarming, hampering all
conclusion based on these PROMs. Considering the results, the PAD quality of life questionnaire (PADQOL),
Intermittent claudication questionnaire (ICQ) and the Vascular quality of life questionnaire (VascuQol) might be
appropriate PROMs for health related quality of life, while the Walking impairment questionnaire (WIQ) and
Estimate ambulation capacity by history questionnaire (EACH-Q) appear suitable PROMs for functional status.
However, all PROMs require further validation studies to ﬁll the gaps in their measurement properties. The
shortcomings highlighted in this review should be taken into account when interpreting PROM results.
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Intermittent claudication (IC) due to peripheral arterial
disease (PAD) is a chronic and disabling condition, which
may severely limit the functional status and health related
quality of life of patients.1e3 Treatment of patients with IC is
aimed at symptom relief and improving walking distance,
and subsequently functional status and health related
quality of life.
Functional status and health related quality of life can be
assessed using patient reported outcome measures
(PROMs). Even though the term “PROM” was not widely
applied, in 2000 the trans-Atlantic Society Consensus (TASC)
recommended that all trials should use a quality of life
(QoL) instrument, and that an accurate measurement of
QoL should be the “ultimate goal”.4
PROM terminology should be clear before they are used,
so physicians and researchers understand what PROMs
intend to measure and represent. Health is deﬁned by the
World Health Organization (WHO) as a state of complete
physical, mental, and social well being and not merely the
absence of disease or inﬁrmity.5 QoL is deﬁned by the WHO
as individuals’ perception of their position in life in the
context of culture and value systems in which they live and
in relation to their goals, expectations, standards, and
concerns.6 Thus, QoL is only partially determined by an
individual’s health. When assessing disease severity and
evaluating treatment results, clinicians, and researchers are
usually interested in the aspects of QoL that are most
related to health, health related QoL, and functional status.
Health related QoL can be deﬁned as the aspects of QoL
that relate speciﬁcally to a person’s health.7 Health status is
deﬁned as the inﬂuence of disease on physical, emotional,
and social functioning.8 The deﬁnition of health status in-
dicates an objective inﬂuence of disease on an individuals’
functioning. However, when using health status and health
related QoL instruments, the outcome is always subjective,
since it is the patient who ﬁlls the instrument. Therefore,
health status and health related QoL instruments essentially
measure the same thing and we have chosen to aggregate
the results on health status and health related QoL in-
struments. Functional status is the ability of the individual
to perform particular deﬁned tasks, and thus only concerns
the physical functioning aspect of health related QoL.7
Both generic and disease speciﬁc PROMs can be used for
patients with IC. Disease speciﬁc PROMs are often consid-
ered more sensitive than generic PROMs because they were
speciﬁcally developed for well deﬁned patient populations.
Validation studies of high quality on all different measure-
ment properties of a PROM are essential before applying
them in practice. Two reviews provided an overview of the
available PROMs for patients with PAD.9,10 Since these re-
views did not systematically assess the methodological
quality of the validation studies on the respective PROMs,
important information on their measurement properties is
lacking.
The aim of the present study was to critically appraise,
compare, and summarize the quality of the measurementproperties of all available disease speciﬁc PROMs for IC,
measuring health related QoL/health status or functional
status, in order to provide evidence based guidance to cli-
nicians and researchers for selecting a PROM.
METHODS
The protocol of this review was not published or registered
in advance.Search strategy
Medline was searched through Pubmed (last search
November 18, 2013) and Embase (1980 to November 18,
2013) through OVID with the assistance of a clinical
librarian. The terms “intermittent claudication”, “arterial
occlusive disease”, “lower extremity ischemia”, “limb
ischemia”, “peripheral arterial disease” and derivatives in
both MESH terms and text words to identify studies con-
cerning the target population were used. These terms were
combined with a search ﬁlter developed to identify studies
on PROMs (developed by the PROM group and the
knowledge center, university of Oxford, department of
public health). It contains the terms “quality of life”, “in-
strument”, “PRO”, “measure”, derivatives, and related terms.
In order not to miss any relevant studies the names of the
instruments already known were included. The full search
strategy is available in Appendix 1 (online only).Eligibility criteria
Eligible studies were full text articles (a) about the devel-
opment or validation of a disease speciﬁc PROM aiming to
measure health related QoL, health status, or functional
status (b) for patients with IC. Studies considering PAD
patients in general were also included as long as patients
with IC were part of the study population and speciﬁed as
such. Excluded were articles (a) concerning patients with
critical limb ischemia only or (b) clinical trials using a rele-
vant disease speciﬁc PROM as outcome measure, or (c)
articles in languages other than Dutch, English, French,
German, Italian, or Spanish.Selection of studies
Two reviewers (AC, SJ) independently assessed eligibility of
studies by screening titles and abstracts according to the
criteria described above. After the initial selection, full text
articles were retrieved and assessed again independently by
the same authors (AC, SJ). Discrepancies were solved by
discussion. If necessary, a third author (CT) was asked to
decide on possible inclusion.Data extraction
The following general characteristics were retrieved: (a)
instrument; (b) the construct aimed to measure; (c) mea-
surement properties evaluated; (d) mode of administration;
(e) country and language; (f) study population; (g) diag-
nosis; (h) number of patients; (i) age; (j) gender; (k) setting.
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In order to provide a global overview of the domains
measured in each of the included questionnaires questions
were categorized according to the domains of one of the
most frequently used QoL conceptual models by Wilson and
Cleary.7 This model describes the pathway from biological
and psychological variables to overall QoL, with symptom
status, functional status, and health perception in between.
This division may provide the reader with a general idea
about the content of the questionnaires, and may serve as
an aid when selecting the most appropriate instrument.Evidence on measurement properties
Measurement properties. Measurement properties are
divided into three domains: reliability, validity, and
responsiveness. A short description of these concepts is
provided according to the COnsensus-based Standards for
the selection of health Measurements Instruments (COS-
MIN) taxonomy.11 The standards of the COSMIN initiative
were chosen since they were established in an international
Delphi study with all relevant expertise involved. (www.
cosmin.nl) A critical appraisal tool, which will be described
later, is part of the initiative.
Reliability is deﬁned as the extent to which scores for
patients whose disease status has not changed are the
same for repeated measurements on different occasions,
for example, at a 1 week interval, or by different in-
terviewers. The domain reliability comprises the measure-
ment properties internal consistency, reliability, and
measurement error. Internal consistency, usually expressed
as Cronbach’s alpha, is a measure of the extent to which
items in a PROM (sub) scale are correlated, thus measuring
the same concept. Factor analysis (for structural validity)
should be performed to determine if the items in the scale
form one underlying scale or multiple subscales. A Cron-
bach’s alpha should be calculated for each subscale sepa-
rately. Reliability is the proportion of the total variance in
the measurements which is due to “true” differences be-
tween patients, and is usually expressed as an intraclass
correlation coefﬁcient (ICC). Measurement error is the sys-
tematic and random error of a patient’s score that is not
attributed to true changes in the patients’ disease status.
Validity is the degree to which an instrument measures
the construct it purports to measure. The domain validity
contains the measurement properties content validity and
construct validity. Content validity is the degree to which
the content of an instrument is an adequate reﬂection of
the construct to be measured, which is established by
involving patients and physicians in the ﬁeld in the devel-
opment process of a PROM through qualitative research
such as focus groups or interviews. Construct validity
comprises structural validity, hypotheses testing, and cross
cultural validity. Structural validity is the degree to which
the scores of an instrument are an adequate reﬂection of
the dimensionality of the construct to be measured, and is
typically determined by factor analysis (see also internal
consistency). Hypotheses testing concerns the degree towhich the scores of an instrument are consistent with hy-
potheses based on the assumption that the instrument
validly measures the construct to be measured. While some
dimensions of health related QoL or functional status in-
struments, such as symptoms subscales, may be correlated
with objective measures such as walking distance, no
objective comparator is available for many other subscales
of health related QoL. Therefore, this part of construct
validity is often examined by correlating the new PROM
with relevant existing PROMs or subscales of PROMs. It is
essential that clear hypotheses regarding magnitude and
direction of correlations are speciﬁed in advance. Cross
cultural validity is the degree to which the performance of
the items on a translated or culturally adapted instrument
are an adequate reﬂection of the performance of the items
of the original version of the instrument. However, many
studies on measurement properties only concern the
translation process of an instrument.
Responsiveness is the ability of an instrument to detect
change over time in the construct to be measured, that is,
the ability of the instrument to detect improvement or
deterioration of a patient. This domain contains solely the
measurement property responsiveness. To construct val-
idity, for only some subscales in PROMs is an objective
measure, such as change in walking distance, available to
correlate with the change in PROM scores. For most sub-
scales, change scores on previously validated comparator
PROMs have to be used for responsiveness studies. Pre-
speciﬁed hypotheses are again essential.
Quality assessment. The methodological quality of the
included studies was assessed with the COSMIN checklist.12
The checklist contains 12 boxes (114 items in total), con-
cerning all measurement properties of an instrument.
Detailed information can be found in the manual for this
checklist (www.cosmin.nl). For each study, only the boxes
concerning the measurement properties evaluated in that
study are scored. Per item, the methodological quality is
scored on a four point rating scale, that is, excellent, good,
fair, or poor.13 Per box, this results in an overall score for
methodological quality, according to the “worst score
counts” method.13
It is important to note that when a study included both IC
and critical limb ischemia (CLI) patients, the COSMIN boxes
based on the number of IC patients included in the study
were scored. In studies on construct validity, the in-
struments or phenomena with which the PROM scores
were correlated were judged for relevance to patients with
IC speciﬁcally.
All studies were assessed by two authors (AC, SJ) inde-
pendently. Discrepancies were resolved by discussion, or
with the help of a referee (CT).
Levels of evidence synthesis
After collecting all studies per measurement property per
instrument, they were rated for the number of studies on a
measurement property per instrument. Studies in different
languages were considered separately, since the factor
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the number of studies are speciﬁed in Table 1. Subse-
quently, the results of the studies were compared per
measurement property per instrument, to determine a
rating on the quality of the measurement property for that
instrument.
Pre-speciﬁed criteria listed in Table 2, adapted from
Terwee et al.,14 were used. Several aspects were taken into
account: (a) the number of studies that investigated the
measurement property, (b) the COSMIN ratings on meth-
odological quality per measurement property, and (c) the
consistency of the results found in the different studies.
When assessing hypotheses testing and responsiveness, the
appropriateness of the comparator instrument used was
also considered. Different languages were mostly consid-
ered separately.
Finally, a level of evidence was established for all the
investigated measurement properties (see Table 7). For
example, with regard to the internal consistency for a
certain instrument in English, þþ means multiple studies of
fair quality were found OR one study of good quality
showing a Cronbach’s alpha of >.70.
RESULTS
The search strategy resulted in a total of 6908 hits. Refer-
ence checking resulted in three additional eligible studies.
After screening of titles and abstracts, 56 articles were
retrieved for full text reading. In total, 43 studies were
included in this review. An overview of the search process is
provided in Fig. 1.
Table 3 shows the characteristics of the included studies.
Table 4 shows the characteristics of the instruments. Table 5
shows the content of the instruments categorized to the
Wilson and Cleary model.7
Overall quality of the studies
In total, measurement properties were assessed 137 times.
Over half of the COSMIN boxes for these measurementTable 1. Levels of evidence for the quality of the measurement
property.
Level Rating Criteria
Strong þþþ or  Consistent ﬁndings in multiple
studies of good
Methodological quality OR in
one study of excellent
Methodological quality
Moderate þþ or  Consistent ﬁndings in multiple
studies of fair
Methodological quality OR in
one study of good
Methodological quality
Limited þ or  One study of fair methodological
quality
Conﬂicting þ/ Conﬂicting ﬁndings
Unknown ? Only studies of poor
methodological quality
þ ¼ positive rating, ? ¼ indeterminate rating,  ¼ negative
rating.properties were scored as poor. For many measurement
properties there was no information available at all. The
quality of the evaluated measurement properties shown in
Table 6. Table 7 shows the levels of evidence per ques-
tionnaire per subscale.PROMS
Health related quality of life/health status
CLAU-S. The CLAU-S was developed in the German lan-
guage.15 It is unclear whether patients were involved in the
initial development process. Translations are available for
English, French, and Flemish. The original version contained
86 items, but it was shortened to 47 items after it was
regarded too lengthy for clinical use, and sensitivity of some
items was found to be weak.16
Six studies were found evaluating measurement proper-
ties of the CLAU-S.15e20 (Tables 2 and 6). From two papers
reporting on the same study, the most extensive paper to
judge the study on measurement properties was chosen,
whereas the other was used to judge only the translation
process.16,17
Content validity was rated indeterminate since it was
unclear whether patients and experts in the ﬁeld were
involved in the development. Internal consistency was rated
positive, except for the English pain subscale. For the
German and English versions moderate evidence was found
for negative reliability. For French, conﬂicting results on the
social life and mood subscale were found. Evidence for
excellent structural validity was found. Conﬂicting evidence
was found for construct validity in English and German.
Evidence for good cross cultural validity was found for all
available languages. Responsiveness was assessed in the
English version, and evidence for positive responsiveness
was found for the subscales pain and daily life, but only for
improved patients. None of the scales was able to detect
patients whose clinical status had deteriorated. It was
therefore rated as conﬂicting.
ICQ. The ICQ was developed in 2002 by Chong et al. and
aims to measure health related QoL.21 Translations are
available in Turkish and German.22,23
Content validity was rated positive since both experts in
the ﬁeld and patients were involved in the extensive devel-
opment process. Limited evidence for uni-dimensionality of
the ICQ in all languages was found. There was limited evi-
dence in Turkish and German and moderate evidence in
English for positive internal consistency. Limited and mod-
erate evidence exist for positive reliability in Turkish and
English, respectively, but evidence is indeterminate in
German. Construct validity is indeterminate for all languages
due to poor hypotheses testing. The same accounts for the
evaluation of responsiveness for the English version.
PADQOL. The PADQOL is a new health related QoL instru-
ment, and so far only available in English.24
Content validity was rated positive, because of an
extensive development process that started with
Table 2. Quality criteria for measurement properties.
Property Rating Quality criteria
Reliability
Internal consistency þ Cronbach’s alpha(s) 0.70
? Cronbach’s alpha not determined or dimensionality unknown
 Cronbach’s alpha(s) <0.70
Reliability þ ICC/weighted Kappa 0.70 OR Pearson’s r 0.80
? Neither ICC/weighted Kappa, nor Pearson’s r determined
 ICC/weighted Kappa <0.70 OR Pearson’s r <0.80
Measurement error þ MIC >SDC OR MIC outside the LOA
? MIC not deﬁned
 MIC SDC OR MIC equals or inside LOA
Validity
Content validity þ A clear description is provided of the measurement aim, the target population,
the concept(s) being measured, and the item selection. Target population and
experts in the ﬁeld were involved in the development process.
? Not enough information available
 No clear description is provided of the measurement aim, the target
population, the concept(s) being measured, and the item selection, or target
population and experts in the ﬁeld were NOT involved in the development
process.
Construct validity e Structural validity þ Factors should explain at least 50% of the variance
? Explained variance not mentioned
 Factors explain <50% of the variance
Construct validity e Hypothesis testing þ Correlations with instruments measuring the same construct 0.50 OR at least
75% of the results are in accordance with the hypotheses AND correlations
with related constructs are higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
 Correlations with instruments measuring the same construct <0.50 OR <75%
of the results are in accordance with the hypotheses OR correlations with
related constructs are lower than with unrelated constructs
Construct validity e Cross cultural validity þ No differences in factor structure OR no important DIF between language
versions
? Multiple group factor analysis not applied AND DIF not assessed
 Differences in factor structure OR important DIF between language versions
Responsiveness
Responsiveness þ Correlation with changes on instruments measuring the same construct 0.50
OR at least 75% of the results are in accordance with the hypotheses OR AUC
0.70 AND correlations with changes in related constructs are higher than with
unrelated constructs
? Solely correlations determined with unrelated constructs
 Correlations with changes on instruments measuring the same construct <0.50
OR <75% of the results are in accordance with the hypotheses OR AUC <0.70
OR correlations with changes in related constructs are lower than with
unrelated constructs
Adapted from Terwee et al., 2007.14
þ ¼ positive rating; ? ¼ indeterminate rating;  ¼ negative rating; AUC ¼ area under the curve; DIF ¼ differential item functioning;
LoA ¼ limits of agreement; MIC ¼ minimally important change.
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ysis for structural validity and subsequent internal con-
sistency analysis provided moderate evidence for a ﬁve
factor structure, with moderate evidence for positive in-
ternal consistency in all subscales. Construct validity was
assessed by correlating the subscales of the PADQOL with
the SF-36, the Proﬁle of Mood States Questionnaire
(POMS) and the WIQ. Limited evidence was found for
positive construct validity in the physical functioning
subscale, but for negative construct validity in three other
scales.PAQ. The PAQ was developed in the United States in 2003
to evaluate health status in patients with PAD.26
Content validity was rated indeterminate. Both experi-
enced clinicians and patients were involved in the devel-
opment process, but it is unclear how item reduction was
done, and how comprehensiveness was assessed.
Four evaluation studies in English, Dutch, and Korean
were found.26e29 There was limited evidence for positive
structural validity and internal consistency in the Dutch
version. However, factor analysis in the Dutch version
showed a three factor structure, in contrast to the ﬁve
Table 3. Characteristics of the study populations.
Study Instrument Mode of
administration
Country (language) Study
population
Inclusion criteria N Mean
age (years)
Gender
(% female/
% male)
Setting
Health related quality of life/Health status
Dietze15 (1997) CLAU-S Self
administered
Germany (German) Patients with
peripheral
arterial disease
stage II
NR 100 60.1a Approx.
25/75%
Outpatient
clinic
Spengel17 (1997) CLAU-S Translation
only
Germany (German),
UK (English), France
(French), Belgium
(French), Belgium
(Flemish)
Spengel18 (1998) CLAUS (data
from RCT62)
Self
administered
France (French) Intermittent
claudication
40e80 year old patients with
stable claudication symptoms for
a 3 month period prior to
enrolment, pain free walking
distance <500 meters,
subjectively assessed by the
patient
234 Naftidrofuryl
65.6 (9.2)
Placebo 66.2
(8.7)
Naftidrofuryl
86.3%/13.7%
Placebo
85.5%/14.5%
General
practitioners
Boccalon19 (2000) CLAU-S Self
administered
France (French) Intermittent
claudication
Patients between 40 and 80 with
intermittent claudication
without rest pain
157 65.4 (9.9) 17.2%/82.8% General
practitioners
Marquis16 (2001) CLAU-S Self
administered
Germany
(German)
UK (English)
France (French)
Belgium (French,
Flemish)
Intermittent
claudication
Patients with FC stage II PAOD
and possible rest pain
Fr: 157
UK: 102
Ger: 99
B-Fr: 42
B-Fl: 80
Fr: 65.4
UK: 64.8
Ger: 60.1
B-Fr: 63.1
B-Fl: 63.3
Fr: 17/83%
UK: 23/77%
Ger: 23/77%
B-Fr: 17/83%
B-Fl: 28/72%
General
practice and
outpatient
clinic
Mehta9 (2006) CLAUS
VascuQol
Self
administered
UK (English) Intermittent
claudication
ISCVS category II claudicants
with lifestyle limiting
claudication
70 Median
age 70
54%/46% NR
Chong21 (2002) ICQ Self
administered
UK (English) Intermittent
claudication
Appropriate history (pain in
calves, thighs or buttocks after
exercise and relieved by rest),
positive response to ECQ, and
ABI 0.9
124 71 (range
42e91)
39%/61% Outpatient
clinic
Ketenci22 (2009) ICQ Self
administered
Turkey (Turkish) Intermittent
claudication
Resting ABI 0.9 or positive
vascular treadmill test or
documented disease
83 60.7 (7.3) 43%/57% NR
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Table 3-continued
Study Instrument Mode of
administration
Country (language) Study
population
Inclusion criteria N Mean
age (years)
Gender
(% female/
% male)
Setting
Kirchberger23
(2012)
ICQ Self
administered
Germany
(German)
Intermittent
claudication
Medical history, physical
examination, and Doppler,
duplex and treadmill test
81 71 (median) 42%/58% Outpatient
clinic
Treat-Jacobsen24
(2013)
PADQOL Self
administered
USA (English) PAD patients:
Intermittent
claudication to
ischemic rest
pain, tissue loss
and previous
amputation
Clinician referral, participation in
PAD trials and advertisement
295 67.9 (10.6) 25.4%/74.6% NR
Spertus26 (2004) PAQ Self
administered
USA (English) Peripheral
arterial disease
PAD patients selected to
undergo percutaneous
peripheral revascularization
44 68 (11) 45%/55% Hospital
Smolderen27
(2008)
PAQ NR Netherlands
(Dutch)
Peripheral
arterial disease
Patients undergoing non-cardiac
elective vascular repair
(endovascular or open
procedure)
465 65 (10) 30%/70% Hospital
Hoeks28 (2009) PAQ NR Netherlands
(Dutch)
Peripheral
arterial disease
Patients undergoing non-cardiac
elective vascular repair
(endovascular or open
procedure)b
465 66% <70
34% >70
30.5%/69.5% Hospital
Lee29 (2012) PAQ Self
administered
Korea (Korean) Peripheral
arterial disease
ABI 0.9, poor pulses bilaterally
or substantially weaker on either
side in case of popliteal artery or
dorsalis pedis artery, and/or
clinical symptoms of PAD
100 Without SC
55.05 (12.01)
With SC 61.1
(7.32)
Without SC
76%/24%
With SC
38%/62%
Hospital,
cardiologic and
rheumatologic
clinic
Morgan30 (2001) VascuQol Self
administered
UK (English) Lower limb
ischemia
NR Stage
1: 137
Stage
II: 39
Stage I: 69
(53e77)
Stage 2:
67 (39e83)
Stage 1:
30/70%
28.0/
61,5%
Hospital
De Vries31 (2005) VascuQol Self
administered
Netherlands
(Dutch)
Intermittent
claudication
and critical
limb ischemia
PAD patients who needed
imaging workup to evaluate
feasibility and choice of
revascularization, all ABI 0.9 at
rest
443
386c
IC 64 (11)
CLI 65 (12)d
IC 34%/66%
CLI 37%/63%d
Hospital
Mazari32 (2010) VascuQol Self
administered
UK (English) Intermittent
claudication
(femoropopliteal
disease)
Recruited from RCT comparing
PTA, SEP and combined
treatment
178 Median
age 70
29.3%/60.7% Hospital
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Nordanstig33
(2012)
VascuQol Self
administered
Sweden
(Swedish)
Peripheral
arterial
disease
Established diagnosis of PAD 200 70 (9) 43%/57% Hospital
Frans34 (2012) VascuQol Self
administered
Netherlands
(Dutch)
Intermittent
claudication
ABI 0.9 and or reduction of
0.15 or more after exercise and
planned conservative treatment
40 67 (44e87) 37%/63% Outpatient
clinic
Functional status
Ouedraogo35
(2011)
EACH-Q
WIQ
Self
administered
France
(French)
Intermittent
claudication
History of revascularization
(surgery/PTA) for lower
extremity arterial disease or
radiological investigation with
stenosis/occlusion of lower
extremities or ABI <0.9 at rest
218 62 (11) 18/82% Hospital,
vascular
laboratory
Ouedraogo36
(2013)
EACH-Q Self
administered
France
(French)
Intermittent
claudication
All new patients who were able
to walk and are referred for
suspected PAD
434 63.7 (11) 20%/80% Hospital,
vascular
center
Regensteiner37
(1990)
WIQ Interviewer
administered
USA (English) Intermittent
claudication
Patients with typical history of
claudication and patients with
ABI <0.95 at rest or <0.85 after
exercise
26 Controls
61  4
Exercise
59  4
Surgery
64  5
3.8%/96.2% Hospital
McDermott38
(1998)
WIQ Self
administered
US (English) Peripheral
arterial disease
ABI <0.9 PAD
146
Controls
65
PAD 71.7
(9.8)
Controls
67.9 (7.7)
PAD
44.5%/55.5%
Controls
46.2%/53.8%
Hospital
Coyne39 (2003) WIQ Telephone
administered
and Self
administered
USA (English) Peripheral
arterial disease
ABI 0.9 at rest 60 67.1a 22%/78% Cardiology
clinics
Collins40 (2004) WIQ NR USA (English,
Spanish)
Peripheral
arterial disease
Patients who received health
care at one of four primary care
clinics in Houston,
PAD ¼ ABI 0.9
403
English
322
Spanish
81
English
speaking
64 (7.4)
Spanish
speaking
63 (6.6)
Spanish
speaking
patients
63%/37%e
Primary
care clinics
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Table 3-continued
Study Instrument Mode of
administration
Country (language) Study
population
Inclusion criteria N Mean
age (years)
Gender
(% female/
% male)
Setting
Izquierdo41 (2005) WIQ Self
administered
US (English) Intermittent
claudication
Fontaine stage II PAD,
intermittent claudication on
Rose questionnaire, lower
extremity pain during a
screening treadmill test and ABI
<0.97 or drop of ABI to 0.85
during exercise
80 71 (6) 9%/91% Vascular
clinics, senior
citizen centers
(and recruited
through
advertisement)
Spertus26 (2004) WIQ Self
administered
USA (English) Peripheral
arterial disease
PAD patients selected to
undergo percutaneous
peripheral revascularization
44 68 (11) 45%/55% Hospital
Ritti Dias42 (2008) WIQ Interviewer
administered
Brazil
(Portuguese)
Intermittent
claudication
FC II, being able to walk for
2 minutes at 3.2 km/h
42 65.2 (8.3) 31%/69% NR
Verspaget43 (2009) WIQ Self
administered
Netherlands
(Dutch)
Intermittent
claudication
Walking distance <750 m on
treadmill test
130 64.5 (10.1) 37%/63% Outpatient
clinic
Nicolaï44 (2009) WIQ Self
administered
Netherlands
(Dutch)
Intermittent
claudication
ABI 0.9 or decreasing 0.15
after exercise
91 66.2 (9.6) 38.5%/61.5% Outpatient
clinic
Matsuo45 (2010) WIQ Self
administered
Japan (Japanese) Peripheral
arterial disease
ABI <0.9 who were receiving
treatment at participating
institutions
169 73.5 (10.3) 42%/58% 74 participating
institutions in
Japan
Nakashima46
(2010)
WIQ Interviewer
administered
Japan (Japanese) Intermittent
claudication
Patients who underwent limb
bypass surgery
31 72.6 (3.31) 12.9%/87.1% Hospital
Yan47 (2011) WIQ NR China (Chinese) Peripheral
arterial disease
ABI <0.9. Half of sample
recruited with ABI <0.6
134 71 (9.0) 29.8%/70.2% Outpatient
clinic
Jie Wang48 (2011) WIQ Self
administered
China (Chinese) Peripheral
arterial disease
and T2DM
ABI 0.9 59 73.41 (9.52) 42.4%/57.6% Diabetic care
and research
center
Mahe49 (2011) WIQ
EACH-Q
Self
administered
France (French) Intermittent
claudication
ABI <0.9 at rest or radiological
investigation with stenosis>50%
of lower extremities or history of
revascularization for lower
extremity arterial disease or
abnormal result for
transcutaneous oxygen pressure
index (below negative 15 mmHg)
at least on one side
310 62.7 (11.3) 20%/80% Hospital,
vascular
laboratory
Sagar50 (2012) WIQ Self
administered
Canada (English) Peripheral
arterial disease
Resting ABI 0.9 123 66.5 (9.4) 29.3%/70.7% Hospital
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Figure 1. Flow diagram.
Quality of PROMs for Intermittent Claudication 325factor structure in the original questionnaire in English.
There was limited evidence for positive internal consistency
in all three subscales. Limited evidence was found for a
positive reliability for the English version, but it was either
not or was inadequately studied in other languages.
Construct validity was rated indeterminate for all scales in
all languages due to poor quality of the validation process.
Responsiveness was also rated indeterminate for English,
and was not studied for other languages.
VascuQol. Originally developed by Morgan in 2001, the
VascuQol has since then been translated into multiple
languages including Dutch and Swedish.20,30e34
Content validity was rated positive, because of an
extensive development process among patients with both
IC and CLI and experts in the ﬁeld involved. Structural val-
idity was never assessed for the VascuQol, and conse-
quently internal consistency is impossible to determine.
Reliability was rated indeterminate due to small samples.
There was limited evidence for positive construct validity in
the Dutch Pain and Activities scales, but for negative
construct validity for the Emotional and Social scales.
Limited evidence for positive responsiveness was found
only for the Pain and Symptoms scales in Dutch. All others
were indeterminate or conﬂicting.Functional status
EACH-Q/WELCH. The EACH-Q was developed in 2011 as a
measure of walking impairment,35 and was speciﬁcally
aimed to develop a short instrument, in order to keep the
error rate low. The EACH-Q was revised and renamed
Table 4. Characteristics of the instruments.
Name Country
(language)
of develop.
Response options Range of scores Recall
period
Mode of admin Language versions
available
Availability
Health related quality of life/Health status
CLAU-S (Dietze, 1997)15 Germany
(German)
4 or 5 point Likert
scale, VAS for pain
rating
0e100 (worst e best) Unclear Self administered German
Dutch (Belgium)
French
English
Copyright by Merck,
contact for more information
ICQ (Chong, 2002)21 UK (English) 5 or 6 point
adjectival scales
0e100 (best -worst) 2 weeks Self administered English(UK)
German Turkish
Unclear
PADQOL (Treat-Jacobsen,
2013)24
USA (English) 6 point Likert scales Range per subscale
(widest 9e54)
(worst e best)
Current
situation
Self administered English (USA) Contact author by email
PAQ2 (Spertus, 2004)26 USA (English) 5,6, or 7 point Likert
scales with equidistant
gradiations
0e100 (worst-best) 4 weeks Self administered English (UK) Available through
www.cvoutcomes.org
VascuQol (Morgan, 2001)30 UK (English) 7 point Likert scales 1e7 (worst-best) Two weeks Self administered English (UK)
Dutch
(Netherlands)
Swedish
Available from author
Functional status
EACH-Q/WELCHa
(Ouedraogo, 2011)19
France (French) Weighted score
per item
0e100% (worst -best) Current
situation
Self administered English (UK)
French
Copyright by university
of Angers
WIQ (Regensteiner 1990)34 USA (English) Weighted items 0e1 (worst-best) 1 week Interviewer/
Telephone/Self
administered
Multiple Available from author
a EACH-Q was revised and named WELCH in later studies.
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Table 5. Content comparison of scale level (number of items).
Patient reported outcome measures in intermittent claudication
Instrument Item distribution in Wilson&Cleary model Total number
of items
Average
completion
time (minutes)
Symptoms Functional status General health
perceptionsSymptoms Pain Physical Social Role Psychological
Health related quality of life/Health status
CLAU-Sa 10 9 4 11 13 47 15
ICQ 1 9 1 2 2 1 16 3.7
PADQOL 8b 9 3 7 11 38 9
PAQ 4 6 1 2 2 5 20c NR
VascuQoL 4 4 8 2 7 25 9.6
Functional status
EACH-Q/WELCH 4 4 2
WIQd 13 13 5
a Instrument was revised over time, details of short version presented.
b Subscale ‘symptoms and limits in physical functioning’.
c One question deﬁning the most affected leg is also included in the questionnaire.
d Instrument was revised over time, data on most commonly used distance/speed/stair climbing version presented.
Table 6. Methodological quality of each study per questionnaire and measurement property.
Questionnaire/Study Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypotheses
testing
Cross cultural
validity/
Translation
Responsiveness
Health related quality of life/Health status
CLAU-S
Dietze 199715 Poor Fair Fair
Spengel 199717 Poor
Spengel 199818 Poor Poor
Boccalon 200019 Poor Fair Poor Poor
Marquis 200116 Good Fair Excellent Gooda
Mehta 20069 Fair Fair
ICQ
Chong 200221 Good Good Fair Fair Poor Poor
Ketenci 200922 Fair Fair Fair Poor Fair
Kirchberger 201223 Fair Poor Fair Fair Poor Good
PADQOL
Treat-Jacobsen 201224 Good Good Good Fair
PAQ
Spertus 200426 Poor Fair Poor Poor
Smolderen 200827 Fair Fair Poor Good
Hoeks 200928 Poor
Lee 201229 Poor Poor Poor Poor Good
VascuQol
Morgan 200130 Poor Poor Fair Poor Poor
De Vries 200531 Fair Fair
Mehta 20069 Fair Fair
Mazari 201032 Poor Poor
Nordanstig 201233 Poor Poor Poor Poor Poor
Frans 201213 Poor Poor Fair
Functional status
EACH Q/WELCH
Ouedraogo 201135 Fair
Mahe 201136 Fair
Tew 201352 Fair
Ouedraogo 201336 Poor Fair
WIQ
Regensteiner 199037 Poor Poor Poor Poor
McDermott 199838 Fair
Coyne 200339 Poor Fair Poor
Stair climbing
subscale
Fair
Other subscales Good
Collins 200440 Poor Poor
Continued
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Table 6-continued
Questionnaire/Study Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypotheses
testing
Cross cultural
validity/
Translation
Responsiveness
Spertus 200426 Poor Fair
Izquierdo 200541 Poor
Ritti Dias 200842 Poor Poor Fair Fair
Verspaget 200953 Poor Fair Poor Poor
Nicolaï 200944 Fair
Matsuo 201045 Poor
Nakashima 201046 Poor
Ouedraogo 201135 Fair
Yan 201147 Poor Fair Fair Fair Poor
Jie Wang 201148 Poor Fair Fair Fair Poor
Mahe 201149 Fair
Sagar 201250 Fair
Abraham 201251 Fair
Tew 201352 Fair
Lozano 201353 Poor Poor Poor Poor
Ouedraogo 201336 Fair
a Cross cultural validity was evaluated in this study, with factor analysis in both the original and the new populations.
Table 7. Levels of evidence per questionnaire per measurement property.
Questionnaire/
Subscale
Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypotheses
testing
Cross
cultural
validity
Responsiveness
Health related quality of life/Health status
CLAU-S
CLAU-S ? þþþ
English þþ
Daily life þþ e ? þ/a
Pain e e þ þ/a
Social life þþ þ þ e
DSF þþ e ? e
Mood þþ e ? e
German þþ
Daily life þþ e e
Pain þþ e þ
Social life þþ e e
DSF þþ e e
Mood þþ e ?
French þþ
Daily life þþ þþ
Pain þþ þþ
Social life þþ þ/
DSF þþ þþ
Mood þþ þ/
Flemish þþ
Daily life þþ þ
Pain þþ þ
Social life þþ þ
DSF þþ þ
Mood þþ e
ICQ
ICQ þ
English þþ þþ þ ? ?
Turkish þ þ þ ?
German þ ? þ ?
PADQOL
PADQOL þ þþ
SR&I þþ e
SC&F þþ e
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Table 7-continued
Questionnaire/
Subscale
Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypotheses
testing
Cross
cultural
validity
Responsiveness
S&PF þþ þ
F&U þþ e
PA þþ ?
PAQ
PAQ ?
English
All subscales ? þ ? ?
Sumscore ? þ ? ?
Dutchb þ
All subscales þ ?
Sumscore ?
Korean ? ? ?
VascuQol
VascuQol þ
English þ/c
All subscales ? ? ?
Dutch
Pain ? ? þ þ
Activities ? ? þ ?
Symptoms ? ? ? þ
Emotional ? ? e ?
Social ? ? e ?
Swedish
All subscales ? ? ?
Functional status
EACH-Q/WELCH
Each Q ?
French þþ
EnglisheUK þ
WELCH
French þ
WIQd Evidence for total scores
WIQ ?
D/S/Sym
English e USe ? ? ? ?
D/S/Sym/SC
Spanish e US ?
English e USe ?
D/S/SC
English e UKe þ/f
English e USe NA þþ
Dutch ? þ ? þ
Chinese ? þþ ? þþ
French þþ
Portuguese ? ? NA
D/S/SC/P
English e US ? NA ? ?
Chinese ? þþ ? þþ
D/S/P
Japanese ?
WIQd Evidence per subscaleg
Distance
English e US þþ þþ
Dutch þ
Chinese þþ þþ
French þþh
Portuguese e
Speed
English e US þþ þþ
Continued
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Table 7-continued
Questionnaire/
Subscale
Internal
consistency
Reliability Measurement
error
Content
validity
Structural
validity
Hypotheses
testing
Cross
cultural
validity
Responsiveness
Dutch þ þ
Chinese þþ þþ
French þþh
Portuguese e
Stairclimbing
English e US þ/ þ
Dutch þ e
Chinese þþ ?
French þ/
Portuguese e
Pain
English e US e
Chinese þ ?
NA ¼ not assessed; DSF ¼ disease speciﬁc fears subscale; F&U ¼ fear and uncertainty subscale; PA ¼ positive adaptation subscale;
S&PF ¼ symptoms and limitations in physical functioning subscale (PADQOL); SC&F ¼ self concepts and feelings subscale (PADQOL);
SR&I ¼ social relationships and interactions subscale (PADQOL); WIQ ¼ walking impairment questionnaire; D/S/Sym ¼ combination
distance, speed, symptoms subscales; D/S/Sym/SC ¼ combination distance, speed, symptoms, stair climbing subscales; D/S/
SC ¼ combination distance, speed, stair climbing subscales; D/S/SC/P ¼ combination distance, speed, stair climbing, pain subscales; D/
S/P ¼ combination distance, speed, pain subscales.
a The domains ‘pain’ and ‘everyday life’ were responsive in improved patients, but not in deteriorated patients.
b Factor analysis in Dutch version showed a three factor solution, which is different from the original seven factor solution in the English
version.
c Only information on sumscore. The VascuQol was responsive for improved patients, but not for deteriorated patients.
d Several versions of the WIQ were used overtime. The results per version of the questionnaire are presented.
e English for US and UK were presented separately since the US version used blocks and the UK version used meters. English for Canada
was included in English for US analysis since blocks were also used.
f Only a sumscore was used in the one study in the UK on the WIQ.
g When overall scores were scored with a question mark, those studies were not considered for the evidence per subscale.
h One study found correlations >0.5 in patients under 70, but correlations <0.5 in patients over 70 years of age.48
330 A.P. Conijn et al.WELCH later, when an item on running was replaced by a
question on self reported walking speed.36
Content validity was rated indeterminate since it is un-
clear whether patients were involved in the development
process. Limited evidence and moderate evidence for pos-
itive construct validity was found, for English and French
respectively, for the EACH-Q. Limited evidence was found
for positive construct validity for the WELCH.
WIQ. The WIQ measures patients’ perception of walking
impairment. Several modiﬁcations of the WIQ have
emerged since its development in 1990.37 The symptoms
subscale of the original version is currently often replaced
by a stair climbing scale, but studies using a WIQ with an
added Pain scale were also found.26,35,36,38e53 Owing to the
different versions of the WIQ, it was sometimes possible to
pool the evidence only per subscale, and not for the entire
instrument (Table 7).
Since it appears that patients were never involved in the
development process, content validity was rated indeter-
minate. Structural validity was never assessed. Conse-
quently, there is no evidence on internal consistency. Both
limited and moderate evidence for good reliability for most
subscales was found. The same holds for construct validity.
Details are displayed in Table 7. Responsiveness was properly
studied for the Dutch version, and provides limited evidence
for positive responsiveness for the speed subscale only.Notably, although the WIQ is a relatively short instru-
ment, several studies found a large number of missing items
or errors, such as the study by Ouedraogo et al.,35 in which
52% of the WIQs had to be corrected for errors.
Other instruments. Apart from the previously described
PROMs, few studies on the Artemis, AUSVIQUOL, PAVK-86,
SIP-IC, and ST-22 were found. These instruments were
evaluated in only a very few studies, or are no longer used
to the author’s knowledge.54e60 Therefore they will not be
discussed in depth. Evidence on these PROMs is left out of
all tables, but is available upon request.DISCUSSION
Ten disease speciﬁc instruments measuring health related
QoL/health status and two measuring functional status for
patients with IC were identiﬁed. Measurement properties
of these 12 instruments were evaluated in 43 studies only.
Unfortunately, most of the evaluation studies were of poor
quality.
Considering the lack of available evidence, the PADQOL,
ICQ, and VascuQol may currently be regarded the most
appropriate disease speciﬁc health related QoL/health status
PROMs to use for patients with IC. The development of these
questionnaires involved patients and experts in the ﬁeld,
ensuring they contain relevant items for patients with IC. In
Quality of PROMs for Intermittent Claudication 331addition, patients were interviewed about the comprehen-
siveness and length of the questionnaire to prevent missing
items, double responses, and incomplete questionnaires.The
development process of both the WIQ and the EACH-Q was
rated indeterminate, hindering a recommendation for a
functional status instrument. Even though theWIQwasmore
extensively studied, there is some evidence patients have
more difﬁculty ﬁlling the WIQ than the EACH-Q.36 More
research on both PROMs is required.
Many measurement properties on various PROMs have
never been studied properly. One important issue concerns
the structural validity of the PROMs. Factor analysis can be
used to determine whether an instrument consists of one
single underlying construct, or whether it comprises different
subscales. Providing evidence for the existence of a subscale
structure of an instrument is important for acceptable
outcome reporting per subscale. Determination of internal
consistency, that is, the assessment of interrelatedness of
items in a subscale or single construct, only makes sense
when the structure of an instrument is clear.The evidence for
internal consistency was rated as poor in many studies, since
factor analysis had never been performed.
A second issue relates to construct validity, which can be
regarded as the degree to which the instrument actually
measures what it intends to measure. The evidence for
construct validity was limited in the recommended PROMs,
and absent for the ICQ. Proper studies on correlations with
other relevant health related QoL or functional status
measures, with pre-speciﬁed hypotheses and a sufﬁcient
sample size, should be performed to ﬁll this evidence gap.
Essential in this validation process is that the measurement
properties of the comparator instruments have been stud-
ied properly, to justify any conclusion on correlations.
Furthermore, it was found that reliability andmeasurement
error were studied for the ICQ andWIQ, and not for the other
recommended instruments. This is a very important ﬁnding,
since accurate and reproducible measurements are pre-
requisites for a measurement instrument. The reason for this
drawback is the poor quality of the many studies on reliability,
which were often performed in too small patient samples.
Finally, very few studies on responsiveness for any of the
instruments were found. Therefore, there is no instrument
available that has been shown to detect change over time
properly. This is an alarming ﬁnding, since PROMs are
frequently used in clinical trials and outcomes research and
there is a call to use them as indicators for quality of care.
All of the PROMs found in this review are based on
classical test theory (CTT). Over recent years, Item Response
Theory (IRT) and Rasch analysis (a form of IRT) have caused
a paradigm shift in the ﬁeld of PROMs, as they for example
enable computer adaptive testing. Since it is beyond the
scope of this review to elaborate on this, a summary of
these theories can be found here.61 Shortly after the search
strategy was conducted, the ﬁrst study on a PROM for IC
based on Rasch analysis was published, concerning the
VascuQol-6.62 Furthermore, in the past decade, many new
initiatives concerning PROMs have been formed, such as
PROMIS and COMET. Formed in 2004, PROMIS aims “toprovide clinicians and researchers access to efﬁcient, pre-
cise, valid and responsive adult and child reported measures
of health and well being”. The website provides an exten-
sive overview of ongoing research as well as background
information on measurement theories. (www.nihpromis.
org). The COMET (Core Outcome Measures in Effective-
ness Trials) initiative intends “to develop core outcome sets
that represent the minimum that should be measured and
reported in all clinical trials of a speciﬁc condition, and are
also suitable for use in clinical audit or research other than
randomised trials” (www.comet-iniative.org). While new
techniques and initiatives may greatly improve and unify
outcome reporting, as yet there are no disease speciﬁc item
banks available for IC, and the currently available in-
struments will have to sufﬁce until there are.
In conclusion, the quality of studies on measurement
properties of available disease speciﬁc PROMs for IC is
worrisome. As long as no proper validation studies are car-
ried out, this hampers all conclusions based on these PROMs.
It seems sensible to perform extensive validation of a few
selected PROMs. This would not only strengthen the ﬁndings
on these PROMs, but would also improve uniformity in
reporting outcomes. Regarding, the quality of the current
PROMs, the VascuQol, PADQOL, and ICQ seem the most
appropriate health related QoL PROMs for further validation.
For functional status, both the WIQ and EACH-Q require
additional studies on measurement properties. The ﬁndings
in Table 7 may serve as a starting point for future research.
This review has several limitations. First, only Embase and
Medline were searched and a language restriction was used.
Even though extensive reference checking was carried out,
relevant papers may have been missed. Second, trials using a
PROM as outcome measure have not been included. How-
ever, since these trials seldom calculate correlations between
the PROM and other existing measures, and raw data are not
available, including these studies would have yielded very
little information on the measurement properties of PROMs.
Third, although a systematic analysis of the available litera-
ture guided by the COSMIN checklist was done, appraisal of
the methodology and aggregating the evidence is to a certain
extent based on the authors’ judgment, and therefore partly
subjective. Yet, the COSMIN checklist with the rating authors
(AC, SJ) was pre-tested and this was discussed this with a
third author (CT) to achieve consistency in scoring, as rec-
ommended by COSMIN.63 Moreover, there is a possibility
that validation studies with negative results have never been
published, thus resulting in publication bias.CONCLUSION
There are many disease speciﬁc PROMs for health related
QoL and functional status available for patients with IC, but
their measurement properties are often insufﬁciently
studied, hampering any conclusion based on these PROMs.
Considering the results of this review, the PADQOL, ICQ, and
VascuQol appear to be the best PROMs for health related
QoL currently available. The WIQ and EACH-Q come into
consideration as PROMS for functional status. However, all
332 A.P. Conijn et al.these PROMs require further validation studies to ﬁll the
gaps on their measurement properties. The shortcomings
highlighted in this review should be taken into account
when interpreting the results of clinical trials and when
using these PROMs as indicators for quality of care.
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